RxDoctor Payments Data

Matthew Dahl, MD

Otolaryngology · Salt Lake City, UTNPI 1679666556

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,255 of the $11,541 with a category attached, or 71.5%. 18 manufacturers reported payments, led by Genentech USA, Inc. at 52.3% of the total. Reporting peaked in 2020 at $6,225 and has fallen 96.0% since, to $252 in 2025. Among otolaryngology clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,541in general payments, 2019–2025

Across 60 payments — averaging $192.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$6K
  • Ambu Inc.$4K
  • Stryker$443
  • Sanofi$396
  • Optinose US, Inc.$128
  • GSK$110
  • plus $427 from 12 others

What the payments were for

  • Consulting fees$8,25572%
  • Travel & lodging$1,48913%
  • Food & beverage$1,79716%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,541 in reported general payments places this provider in the 95th percentile of 104 otolaryngology providers in Utah.

See all otolaryngology providers in Utah

Medicare billing

Part B allowed, 2024
$14,364
Medicare patients
81
Services billed
159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide34$1,142
Ofloxacin11$578
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$181

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →